COMMUNIQUÉS West-GlobeNewswire
-
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
27/10/2025 -
Amwell® to report third quarter 2025 operating results; company leaders to attend upcoming investor conferences
27/10/2025 -
Elixir Medical annonce de nouveaux résultats cliniques significatifs pour le DynamX® Bioadaptor, démontrant une réduction de près de 50 % des taux d’événements coronariens par rapport à la norme actuelle de soins ICP
27/10/2025 -
Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard of Care
27/10/2025 -
Aurora Spine Launches New Biologics Portfolio
27/10/2025 -
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
27/10/2025 -
Protext Mobility, Inc. (OTC: TXTM) Ignites Next Phase of Growth with Investor Relations Presentation Initiative — Setting the Stage for a New Era of Transparency and Acceleration
27/10/2025 -
LifeLabs Care Packages Bring Comfort to Children with Cancer at POGO Satellite Clinics
27/10/2025 -
Chiffre d'affaires au 30 septembre 2025
27/10/2025 -
Revenue for the nine months ended 30 September 2025
27/10/2025 -
Health Canada Approval of Lecanemab Offers New Hope for Ontarians Living with Alzheimer’s Disease
27/10/2025 -
Fungushead Launches Veteran ‘Angel’s Wing Scholarship’ and Reaffirms Microscopy-Only Standards as California Accelerates Psychedelic Research (AB 1103)
27/10/2025 -
Axis Integrated Mental Health Acquires Best Mind to Combat Colorado’s Mental Health Crisis
27/10/2025 -
Arcutis to Present at Upcoming Investor Conferences
27/10/2025 -
Prenetics Announces Oversubscribed Approximately $48 Million Equity Offering with Potential for $216 Million in Total Proceeds to Fuel IM8’s Global Expansion and Bitcoin Treasury Strategy
27/10/2025 -
MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
27/10/2025 -
Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT
27/10/2025 -
Valneva fera des présentations et rencontrera les investisseurs lors de conférences aux États-Unis et en Europe
27/10/2025 -
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
27/10/2025
Pages